Latest News

Data from the IZALCO trial support the use of subcutaneous on-body injector administration of an isatuximab-based regimen in relapsed/refractory multiple myeloma.

Emphasizing critical thought over a conformity of thought in oncology may help prioritize and advocate for patients with cancer.

BI-1808 plus pembrolizumab was safe and well-tolerated among patients with recurrent ovarian cancer.

Preclinical data from the phase 2 SUMMIT trial presented at the 2025 ASH meeting support the submission for bezuclastinib in this patient group.

Jose G. Trevino, II, MD, FACS, emphasized educating patients and physicians alike to help recognize early signs of pancreatic ductal adenocarcinoma.

Patients with low-risk prostate cancer who have a BMI of 30 or greater experienced a potentially harmful effect after receiving metformin.

Overall survival significantly improved with radiation plus cisplatin/paclitaxel in the phase 2 RTOG 9911 trial over a historical control cohort.

Stereotactic body radiotherapy alone may be feasible instead of immediate systemic therapy in select patients with oligometastatic cancer.

An investigational new drug application for ALA-101 has been submitted to the FDA for the treatment of CD19-positive non-Hodgkin lymphoma and leukemia.

In patients with cancer, there was an increased risk of cardiovascular death vs those who did not have cancer (HR, 2.46).

Patients currently enrolled on the RAMP 203 trial will have the option of continuing treatment with the avutometinib regimen per investigator discretion.

The approval of narsoplimab by the FDA may now prevent fatal complications from stem cell transplants.

The overall safety profile of melphalan/HDS was comparable among relevant subgroups with an absence of cumulative toxicity in successive treatment cycles.

Findings suggest a need for interventions to promote equitable use for underrepresented groups and promote PRO use in those with higher symptom burden.

Nurses preferred the FreedomEDGE infusion system compared with the manual push technique in a retrospective survey study.

VCU Massey Cancer Center is utilizing L-Dex bioimpedance spectroscopy to move toward a preventative model for lymphedema.

Frequent follow-up to determine if lymphedema has developed is necessary to catch it early and begin rehabilitation processes.

The use of bioimpedance spectroscopy takes under 2 minutes and can help detect lymphedema before symptoms appear.

Although findings did not show differences in eating restrictions 1 month following gastrectomy, the mobile intervention may help with symptom management.

Data from a phase 2 study may support a novel mTOR inhibitor-based regimen in previously treated, HR-positive, HER2-negative breast cancer.

Data from the phase 3b ALIDHE study may enrich knowledge on ivosidenib plus azacitidine’s safety and efficacy in IDH1-mutated acute myeloid leukemia.

The approval of durvalumab plus FLOT for patients with resectable gastric/GEJ cancer cements itself as a new standard of care in the space.

Rahul Banerjee, MD, FACP; and Brooke Adams, PharmD, BCOP, discussed the top hematologic oncology abstracts from the 2025 ASH Annual Meeting and Exposition.

The addition of zovegalisib to fulvestrant led to rapid declines in PIK3CA and ESR1 ctDNA in the HR-positive/HER2-negative advanced breast cancer group.

Clinicians who are experienced with immunotherapy, like durvalumab, can easily identify and manage AEs associated with treatment for gastric/GEJ cancer.

Numerous clinicians spoke about breaking news, clinical trial updates, and the evolution of standard-of-care treatment throughout 2025.

Based on results from the MATTERHORN study of durvalumab/FLOT in gastric/GEJ cancers, the regimen should be considered a new SOC.

Michelle Riba, MD, discusses the evolution of distress screening in oncology and the move toward a collaborative care model to integrate psychosocial support into clinical practice.

From KRAS inhibitors in metastatic CRC to radioligands and PET imaging agents in prostate cancer, dozens of oncologic approvals were reported in 2025.

Yelena Y. Janjigian, MD, provides the background of the MATTERHORN trial, showcasing the importance of durvalumab plus FLOT in gastric/GEJ cancers.

Daniel C. McFarland, DO; and Charles Kamen, PhD, MPH, discuss the unique challenges that sexual and gender minority groups experience in cancer care.